Table 3.
Characteristics of grey literature reports included | Total n (%) | Recommended with conditions (n = 48) | Not recommended (n = 17) | Inconclusive evidencea (n = 6) |
---|---|---|---|---|
Country of studyb (N = 72) | ||||
UK | 32 (44) | 25 | 4 | 3 |
AU | 15 (21) | 9 | 5 | 0 |
Canada | 20 (28) | 12 | 8 | 0 |
Other | 5 (7) | 2 | 0 | 3 |
Intervention studiedb (N = 72) | ||||
Renal cell carcinoma | ||||
Avelumab-with-axitinib | 2 (3) | 1 | 1 | 0 |
Axitinib | 2 (3) | 2 | 0 | 0 |
Cabozantinib based strategiesc | 5 (7) | 5 | 0 | 0 |
Lenvatinib based strategiesd | 4 (6) | 3 | 1 | 0 |
Nivolumab based strategiese | 4 (6) | 4 | 0 | 0 |
Pembrolizumab based strategiesf | 5 (7) | 4 | 1 | 0 |
Sorafenib | 2 (3) | 1 | 1 | 0 |
Sunitinib | 2 (3) | 1 | 1 | 0 |
Otherg | 5 (7) | 4 | 1 | 0 |
Systemic lupus erythematosus | ||||
Belimumab | 3 (4) | 1 | 2 | 0 |
Anifrolumab | 2 (3) | 1 | 1 | 0 |
Atypical hemolytic uremic syndrome | ||||
Eculizumab | 2 (3) | 1 | 1 | 0 |
Ravulizumab | 4 (6) | 4 | 0 | 0 |
Autosomal dominant polycystic kidney disease | ||||
Tolvaptan | 3 (4) | 2 | 1 | 0 |
Fabry disease | ||||
Agalsidase alfa | 1 (1) | 0 | 1 | 0 |
Migalastat | 3 (4) | 3 | 0 | 0 |
Pegunigalsidase | 1 (1) | 1 | 0 | 0 |
Enzyme replacement therapies | 1 (1) | 0 | 0 | 1 |
Other diseases studiedh | 21 (29) | 12 | 4 | 5 |
Includes 1 cost of illness study identified in the grey literature.
Multiple interventions and countries covered in some studies.
Including cabozantinib and cabozantinib plus nivolumab.
Including lenvatinib, lenvatinib plus everolimus, and Lenvatinib plus pembrolizumab.
Including nivolumab and nivolumab-with-ipilimumab.
Including pembrolizumab, pembrolizumab plus axitinib, and pembrolizumab plus lenvatinib.
Including tivozanib, vinflunine, pazopanib, everolimus and bevacizumab (first line), sorafenib (first- and second line), sunitinib (second-line) and temsirolimus (first-line).
Including daratumumab for AL amyloidosis, C3 glomerulopathy, selumetinib for neurofibromatosis type 1, caplacizumab for acquired thrombotic thrombocytopenic purpura, screening programs for genetic diseases, enzyme replacement therapy for lysosmal storage diseases, enzyme replacement therapies for mucopolysaccharidosis type 1, rituximab for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ciclosporin for idiopathic steroid-resistant nephrotic syndrome, cost-of-illness of tuberous sclerosis complex, and burosumab for X-linked hypophosphatemia.